ESPR Projected Dividend Yield
Esperion Therapeutics Inc (New) ( NASDAQ : ESPR )Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s first two products were approved by the U.S. Food and Drug Administration, European Medicines Agency, and Swiss Agency for Therapeutic Products. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. 20 YEAR PERFORMANCE RESULTS |
ESPR Dividend History Detail ESPR Dividend News ESPR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |